NCT01602341

Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Four-Week, Bilateral Study of the Safety and Efficacy of Two Concentrations of AN2728 Ointment Administered Once or Twice a Day in Adolescents With Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 86 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 12 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety and efficacy of AN2728 Topical Ointment, 2% and 0.5%, administered once a day (QD) or twice a day (BID), in the treatment of adolescents with atopic dermatitis (AD)

Conditions

• Dermatitis, Atopic

Interventions

Type	Name	Description
DRUG	AN2728 Topical Ointment, 2% QD	AN2728 Topical Ointment, 2% QD
DRUG	AN2728 Topical Ointment, 0.5% QD	AN2728 Topical Ointment, 0.5% QD
DRUG	AN2728 Topical Ointment, 2% BID	AN2728 Topical Ointment, 2% BID
DRUG	AN2728 Topical Ointment, 0.5% BID	AN2728 Topical Ointment, 0.5% BID

Timeline

• Start date: 2012-08-01
• Primary completion: 2013-01-01
• Completion: 2013-01-01
• First posted: 2012-05-21
• Last updated: 2017-03-06
• Results posted: 2017-03-06

Locations

17 sites across 2 countries: United States, Australia